WO2006069200A3 - Group b streptococcus - Google Patents

Group b streptococcus Download PDF

Info

Publication number
WO2006069200A3
WO2006069200A3 PCT/US2005/046491 US2005046491W WO2006069200A3 WO 2006069200 A3 WO2006069200 A3 WO 2006069200A3 US 2005046491 W US2005046491 W US 2005046491W WO 2006069200 A3 WO2006069200 A3 WO 2006069200A3
Authority
WO
WIPO (PCT)
Prior art keywords
streptococcus
group
vaccines
antibiotics
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/046491
Other languages
French (fr)
Other versions
WO2006069200A2 (en
Inventor
Herve Tettelin
Vega Masignani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2007007033A priority Critical patent/MX2007007033A/en
Priority to US11/793,435 priority patent/US20090104218A1/en
Priority to CA002591510A priority patent/CA2591510A1/en
Priority to JP2007548453A priority patent/JP2008525033A/en
Priority to AU2005319174A priority patent/AU2005319174A1/en
Priority to NZ555934A priority patent/NZ555934A/en
Application filed by Chiron Corp filed Critical Chiron Corp
Priority to EP05857170A priority patent/EP1828231A2/en
Publication of WO2006069200A2 publication Critical patent/WO2006069200A2/en
Publication of WO2006069200A3 publication Critical patent/WO2006069200A3/en
Priority to IL183830A priority patent/IL183830A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Polypeptides and nucleic acids from Streptococcus agalactiae which can be used in the development of vaccines, for diagnostic purposes, and as targets for antibiotics.
PCT/US2005/046491 2004-12-22 2005-12-21 Group b streptococcus Ceased WO2006069200A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US11/793,435 US20090104218A1 (en) 2004-12-22 2005-12-21 Group B Streptococcus
CA002591510A CA2591510A1 (en) 2004-12-22 2005-12-21 Group b streptococcus
JP2007548453A JP2008525033A (en) 2004-12-22 2005-12-21 Group B Streptococcus
AU2005319174A AU2005319174A1 (en) 2004-12-22 2005-12-21 Group B Streptococcus
NZ555934A NZ555934A (en) 2004-12-22 2005-12-21 Polypeptides from the Group B Streptococcus (GBS) and uses thereof in treating and detecting GBS disease or infection
MX2007007033A MX2007007033A (en) 2004-12-22 2005-12-21 Group b streptococcus.
EP05857170A EP1828231A2 (en) 2004-12-22 2005-12-21 Group b streptococcus
IL183830A IL183830A0 (en) 2004-12-22 2007-06-11 Group b streptococcus

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63894304P 2004-12-22 2004-12-22
US60/638,943 2004-12-22
US64043804P 2004-12-30 2004-12-30
US60/640,438 2004-12-30

Publications (2)

Publication Number Publication Date
WO2006069200A2 WO2006069200A2 (en) 2006-06-29
WO2006069200A3 true WO2006069200A3 (en) 2007-03-01

Family

ID=36602309

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/046491 Ceased WO2006069200A2 (en) 2004-12-22 2005-12-21 Group b streptococcus

Country Status (8)

Country Link
US (1) US20090104218A1 (en)
EP (1) EP1828231A2 (en)
JP (1) JP2008525033A (en)
AU (1) AU2005319174A1 (en)
CA (1) CA2591510A1 (en)
IL (1) IL183830A0 (en)
MX (1) MX2007007033A (en)
WO (1) WO2006069200A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8858957B2 (en) 2007-09-12 2014-10-14 Novartis Ag GAS57 mutant antigens and GAS57 antibodies
US8945589B2 (en) 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2281977T3 (en) 1998-12-22 2007-10-01 Microscience Limited STREPTOCOCO PROTEINS OF GROUP B AND ITS USE.
US6890539B2 (en) 1998-12-22 2005-05-10 Microscience, Ltd. Genes and proteins, and their use
US7939087B2 (en) 2000-10-27 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from Streptococcus groups A & B
US7709009B2 (en) 2003-07-31 2010-05-04 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for streptococcus pyogenes
EP1807446A2 (en) * 2004-10-08 2007-07-18 Novartis Vaccines and Diagnostics, Inc. Immunogenic and therapeutic compositions for streptococcus pyogenes
EP1801235A1 (en) 2005-12-20 2007-06-27 Institut Pasteur Rapid detection of the "high virulent" ST-17 clone of Group B streptococcus
CA2654968A1 (en) * 2006-06-19 2008-02-21 Mutabilis Identification of genes implicated in the virulence of streptococcus agalactiae
US20100150943A1 (en) * 2006-07-26 2010-06-17 Novartis Ag Immunogenic compositions for gram positive bacteria
EP2135877A1 (en) * 2008-06-19 2009-12-23 Helmholtz-Zentrum für Infektionsforschung GmbH Marker of steptococcus anginosus/Streptococcus constellatus (Moac) and uses thereof
US8147849B2 (en) 2009-02-20 2012-04-03 Novartis Ag Protective antigens for group B Streptococcus hypervirulent strains
ITMI20090946A1 (en) 2009-05-28 2010-11-29 Novartis Ag EXPRESSION OF RECOMBINANT PROTEINS
JP5931724B2 (en) 2009-06-29 2016-06-08 ジェノセア バイオサイエンシーズ， インコーポレイテッド Vaccines and compositions against Streptococcus Pneumoniae
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
SG10201600435UA (en) 2011-01-20 2016-02-26 Genocea Biosciences Inc Vaccines And Compositions Against Streptococcus Pneumoniae
KR20140026372A (en) * 2011-02-02 2014-03-05 이무노퓨처 아이앤씨. Drug delivery material capable of passing through blood-brain barrier, and peptide and use thereof
EP2557424A1 (en) * 2011-08-11 2013-02-13 InGen Biosciences Method for diagnosing Streptococcus, Enterococcus and Pepstostreptococcus genera infections
CN104321335A (en) * 2012-02-24 2015-01-28 诺华股份有限公司 Pilus proteins and compositions
CN104334736A (en) * 2012-03-30 2015-02-04 纳幕尔杜邦公司 Enzymes useful for the production of peracids
CN104582718B (en) 2012-10-03 2017-10-24 诺华股份有限公司 immunogenic composition
EP3021864A1 (en) * 2013-07-16 2016-05-25 Université de Lausanne Bacterial lysins and uses thereof
BR112017002183A2 (en) * 2014-08-05 2018-01-16 Glaxosmithkline Biologicals S.A. conjugate, pharmaceutical composition, and method for enhancing an immune response in a mammal
AU2017214441B2 (en) 2016-02-04 2021-08-19 Genovis Ab New Streptococcal proteases
WO2018204153A1 (en) * 2017-05-02 2018-11-08 Venomyx, Inc. Composition and methods for treating snake envenomation
WO2018237010A2 (en) * 2017-06-20 2018-12-27 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College VACCINE COMPOSITIONS AGAINST STREPTOCOCCUS AND THEIR METHODS OF USE
PL239045B1 (en) * 2018-01-09 2021-11-02 Inst Immunologii I Terapii Doswiadczalnej Polskiej Akademii Nauk Epitope specific for infectious Streptococcus agalactiae and the method of detecting infection of the patient with Streptococcus agalactiae
GB2590210B (en) * 2018-06-13 2023-01-25 Gen Probe Inc Compositions and methods for detecting group B Streptococcus nucleic acid
KR20210055694A (en) 2018-08-06 2021-05-17 메디카인 인코포레이티드 IL-2 receptor binding compound
MX2022005411A (en) 2019-11-05 2022-08-10 Medikine Inc Il-2rî²î³c binding compounds.
AU2020395148A1 (en) * 2019-12-06 2022-06-23 Theratechnologies Inc. Sortilin binding conjugate compounds, compositions and uses thereof for treating cancer
US11746139B2 (en) 2020-02-03 2023-09-05 Medikine, Inc. IL-7Rαγc binding compounds
AU2021219847A1 (en) * 2020-02-12 2022-10-13 Massachusetts Institute Of Technology Field deployable CRISPR-Cas diagnostics and methods of use thereof
US11453907B2 (en) 2020-03-23 2022-09-27 The Broad Institute, Inc. Crispr effector system based coronavirus diagnostics
WO2022026534A1 (en) * 2020-07-28 2022-02-03 Kansas State University Research Foundation Sars-cov-2 immunogenic compositions and methods for protecting against sars-cov-2 clinical signs
EP4240394A4 (en) * 2020-11-04 2024-10-23 Medikine, Inc. IL-2R BETA-GAMMA C BINDING COMPOUNDS AND USES THEREOF
US11999771B2 (en) 2022-04-07 2024-06-04 Medikine, Inc. IL-7Rαγc ligand immunoglobulin fusion proteins
JP2026525956A (en) * 2023-07-18 2026-08-04 インターベット インターナショナル ベー． フェー． Novel strain of Streptococcus agalactie serotype IA and its vaccine
TW202542195A (en) * 2024-01-08 2025-11-01 美商得納利醫療公司 Compositions and methods for modulating tau expression
WO2025250877A1 (en) * 2024-05-31 2025-12-04 Saliogen Therapeutics, Inc. Mobile genetic elements from myotis myotis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006736A2 (en) * 1998-07-27 2000-02-10 Microbial Technics Limited Nucleic acids and proteins from group b streptococcus
WO2002034771A2 (en) * 2000-10-27 2002-05-02 Chiron Srl Nucleic acids and proteins from streptococcus groups a & b
WO2002092818A2 (en) * 2001-04-26 2002-11-21 Institut Pasteur Streptococcus agalactiae genome sequence, use for developing vaccines, diagnostic tools, and for identifying therapeutic targets

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL95578A (en) * 1989-09-15 1998-08-16 Gen Hospital Corp Conjugate vaccine formed from a polysaccharide and a c protein of b-streptococcus
GB9808327D0 (en) * 1998-04-20 1998-06-17 Chiron Spa Antidiotypic compounds
GB9921125D0 (en) * 1999-09-07 1999-11-10 Microbial Technics Limited Proteins
JP5116971B2 (en) * 2002-10-15 2013-01-09 インターセル アーゲー Nucleic acid encoding an adhesion factor for group B streptococci, an adhesion factor for group B streptococci, and uses thereof
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006736A2 (en) * 1998-07-27 2000-02-10 Microbial Technics Limited Nucleic acids and proteins from group b streptococcus
WO2002034771A2 (en) * 2000-10-27 2002-05-02 Chiron Srl Nucleic acids and proteins from streptococcus groups a & b
WO2002092818A2 (en) * 2001-04-26 2002-11-21 Institut Pasteur Streptococcus agalactiae genome sequence, use for developing vaccines, diagnostic tools, and for identifying therapeutic targets

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE Geneseq [online] 2 July 2002 (2002-07-02), "Streptococcus polypeptide SEQ ID NO 9444.", XP002397445, retrieved from EBI accession no. GSP:ABP30134 Database accession no. ABP30134 *
DATABASE Geneseq [online] 24 February 2005 (2005-02-24), "Streptococcus agalactiae protein, SEQ ID 2383.", XP002397448, retrieved from EBI accession no. GSP:ADV81242 Database accession no. ADV81242 *
DATABASE Geneseq [online] 30 May 2000 (2000-05-30), "Group B Streptococcus protein sequence SEQ ID NO:49.", XP002397447, retrieved from EBI accession no. GSP:AAY91320 Database accession no. AAY91320 *
DATABASE JPO Proteins [online] 17 July 2003 (2003-07-17), "Nucleic acid and protein originating in group B Streptococcus.", XP002397446, retrieved from EBI accession no. JPOP:BD629260 Database accession no. BD629260 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8945589B2 (en) 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
US8858957B2 (en) 2007-09-12 2014-10-14 Novartis Ag GAS57 mutant antigens and GAS57 antibodies
US9102741B2 (en) 2007-09-12 2015-08-11 Novartis Ag GAS57 mutant antigens and GAS57 antibodies

Also Published As

Publication number Publication date
IL183830A0 (en) 2007-10-31
AU2005319174A1 (en) 2006-06-29
WO2006069200A2 (en) 2006-06-29
MX2007007033A (en) 2007-08-03
US20090104218A1 (en) 2009-04-23
CA2591510A1 (en) 2006-06-29
EP1828231A2 (en) 2007-09-05
JP2008525033A (en) 2008-07-17

Similar Documents

Publication Publication Date Title
MX2007007033A (en) Group b streptococcus.
WO2007076132A3 (en) Compositions comprising oriented, immobilized macromolecules and methods for their preparation
IL210485A (en) Isolated antibody or a functional protein, process for its preparation, pharmaceutical composition comprising the same and isolated nucleic acid encoding said antibody or functional protein
WO2008060705A8 (en) Anti-dll4 antibodies and methods using same
WO2008143679A9 (en) Nucleic acids and proteins and methods for making and using them
IL184288A0 (en) 18-methyl-19-nor-17-pregn-4-en-21,17-carbolactones and pharmaceutical preparations comprising the same
IL196426A0 (en) Microparticulates based on an amphiphilic copolymer, processes for the preparation thereof and pharmaceutical compositions containing the same
WO2008108830A8 (en) Immunogenic and therapeutic compositions for streptococcus pyogenes
ZA200700397B (en) Novel benzamidine derivatives, process for the preparation thereof and pharmaceutical composition comprising the same
ZA200900673B (en) 18-methyl-19-nor-androst-4-en-17, 17-spiroether (18-methyl-19-nor-20-spirox-4-en-3-one) and pharmaceutical preparations containing the same
WO2005118813A3 (en) Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with sars corona virus spike protein
WO2007067828A3 (en) Glp-2 mimetibodies, polypeptides, compositions, methods and uses
WO2004042006A3 (en) Amylases, nucleic acids encoding them and methods for making and using them
WO2007117763A3 (en) Methods and compositions for targeting relt
WO2008054595A3 (en) Drug controlled molecular tags
IL193699A0 (en) Proteins, nucleic acids and medicaments
WO2007007325A3 (en) Sp1 polypeptides, modified sp1 polypeptides and uses thereof
WO2005013904A3 (en) Sars nucleic acids, proteins, vaccines, and uses thereof
WO2006047728A3 (en) Bmp gene and fusion protein
WO2006091847A3 (en) Clopidogrel base suitable for pharmaceutical formulation and preparation thereof
WO2006089209A3 (en) Txr1 and enhanced taxane sensitivity based on the modulation of a pathway mediated thereby
WO2006060484A3 (en) Tuberculosis nucleic acids, polypeptides and immunogenic compositions
WO2007108829A3 (en) Tuberculosis nucleic acids, polypeptides and immunogenic compositions
WO2006104761A3 (en) Unique sequence hybridization probes (usp)
WO2006122277A3 (en) Novel targets for the identification of antibiotics that are not susceptible to antibiotic resistance

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200580044265.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 555934

Country of ref document: NZ

Ref document number: 2005319174

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 183830

Country of ref document: IL

Ref document number: 2005857170

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/007033

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2591510

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2005319174

Country of ref document: AU

Date of ref document: 20051221

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007548453

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2701/KOLNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 11793435

Country of ref document: US